Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibitors for Advanced or Metastatic Non-Small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials
OncologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Therapeutic drug monitoring
- Publicado em
- 6 jun 2024
- Citações
- 1
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibitors for Advanced or Metastatic Non-Small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials
Wei Ren, Yingying Fang, Yujing He, Yifeng Ren, Minfang Wang, Anyi Xu, Jiale Ruan, Qinghua Tao
Descritores MeSH
- Programmed Cell Death 1 Receptor
- Carcinoma, Non-Small-Cell Lung
- CTLA-4 Antigen
- Immune Checkpoint Inhibitors
- Lung Neoplasms
- Randomized Controlled Trials as Topic
- B7-H1 Antigen
- Humans
- Immunotherapy